A detailed history of Wetherby Asset Management Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Wetherby Asset Management Inc holds 1,351 shares of ALNY stock, worth $318,241. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,351
Previous 1,149 17.58%
Holding current value
$318,241
Previous $279,000 32.97%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$233.81 - $287.01 $47,229 - $57,976
202 Added 17.58%
1,351 $371,000
Q2 2024

Aug 14, 2024

SELL
$143.31 - $247.0 $42,563 - $73,359
-297 Reduced 20.54%
1,149 $279,000
Q1 2024

May 15, 2024

SELL
$146.51 - $198.2 $25,932 - $35,081
-177 Reduced 10.91%
1,446 $216,000
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $49,359 - $64,081
326 Added 25.13%
1,623 $310,000
Q3 2023

Nov 14, 2023

SELL
$170.77 - $211.65 $43,717 - $54,182
-256 Reduced 16.48%
1,297 $229,000
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $35,336 - $40,501
191 Added 14.02%
1,553 $294,000
Q1 2023

May 12, 2023

SELL
$182.66 - $235.53 $22,467 - $28,970
-123 Reduced 8.28%
1,362 $272,000
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $37,477 - $48,744
-202 Reduced 11.97%
1,485 $352,000
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $233,716 - $391,384
1,687 New
1,687 $338,000
Q2 2022

Aug 15, 2022

SELL
$120.42 - $169.29 $158,111 - $222,277
-1,313 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$127.18 - $173.91 $381 - $521
3 Added 0.23%
1,313 $214,000
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $7,658 - $10,045
48 Added 3.8%
1,310 $222,000
Q3 2021

Nov 15, 2021

BUY
$169.75 - $207.73 $8,657 - $10,594
51 Added 4.21%
1,262 $238,000
Q2 2021

Aug 16, 2021

BUY
$128.63 - $176.89 $155,770 - $214,213
1,211 New
1,211 $205,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Wetherby Asset Management Inc Portfolio

Follow Wetherby Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wetherby Asset Management Inc with notifications on news.